Prof. Dr. Daniel Peeper is professor in Functional Oncogenomics at VU University Amsterdam and a group leader at the Department of Molecular Oncology and Immunology at the Netherlands Cancer Institute (NKI).
He and his research team use function-based genomic approaches to overcome immunotherapy resistance in cancer. Their research increased the understanding of signaling mechanisms between tumor and immune cells, allowing insight into more specific targetable cancer vulnerabilities. They discovered the tumor-suppressing mechanism of oncogene-induced cellular senescence leading to an inflammatory transcriptome, and the sensitization of tumor cells towards T cell attack by lowering the TNF threshold. Their establishment of a large melanoma patient-derived xenograft (PDX) platform allowed insight into several novel resistance mechanisms. Based on the findings of Peeper’s research group, several potential new tumor and immune cell targets have been detected and are currently being tested in preclinical models.
He is member of several boards including the European Association for Cancer Research, Oncode, EMBO, Academia Europeae and he chairs the Research Faculty Council Board at the NKI. He has received several awards including the KWF Queen Wilhelmina Award and the Society for Melanoma Research Outstanding Researcher Award.